Paul Mateo Tovar Cobos

Dr. Paul Mateo Tovar Cobos

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MRMATHIAS SALVATORE RENTEROS RAMIREZ
MATHIAS SALVATORE RENTEROS RAMIREZ
RARenzo Barreto Abanto
Renzo Barreto Abanto
DCDiego Huapaya Cruz
Diego Huapaya Cruz
Paul Mateo Tovar CobosPaul Mateo Tovar Cobos
Paul Mateo Tovar Cobos
ADAlvarado Ramos Richard Daiel
Alvarado Ramos Richard Daiel
JBJoshuan J. Barboza
Joshuan J. Barboza
Background/Objectives: Solanezumab is a humanized monoclonal antibody designed to bind soluble amyloid-beta (Aβ) and facilitate its clearance from the brain, aiming to slow the progression of Alzheimer’s disease (AD). Methods: A systematic search was applied in four medical databases through October 2024 to identify phase 2 or 3 randomized controlled trials evaluating solanezumab in patients aged ≥50 years with mild AD or in preclinical stages. The primary outcomes were changes in cognitive and functional scales, including ADAS-cog14, MMSE, ADCS-ADL, and CDR-SB. Data were pooled using a random-effects model, and certainty of evidence was assessed using GRADE. Results: Seven trials involving 4181 participants were included. Solanezumab did not significantly reduce cognitive decline based on ADAS-cog14 (MD = −0.75; 95% CI: −2.65 to 1.15; very low certainty) or improve functional scores on ADCS-ADL (MD = 0.85; 95% CI: −1.86 to 3.56; very low certainty) and CDR-SB (MD = −0.15; 95% CI: −0.89 to 0.60; very low certainty). A modest but statistically significant improvement was observed in MMSE scores (MD = 0.59; 95% CI: 0.33 to 0.86; moderate certainty). Conclusions: While solanezumab may offer slight benefits in general cognitive performance, its overall impact on clinically meaningful outcomes remains limited. The results do not support its use as a disease-modifying therapy for Alzheimer’s disease in either preclinical or symptomatic stages.

10 July 2026 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
TOTabata L Tinoco Ortiz
Tabata L Tinoco Ortiz
MGMaximo V Torres Guaicha
Maximo V Torres Guaicha
Paul Mateo Tovar CobosPaul Mateo Tovar Cobos
Paul Mateo Tovar Cobos
Swallowable intragastric balloon is a minimally invasive bariatric option for obesity, but severe intolerance requiring intervention is uncommon. We report a 41-year-old man with grade I obesity, hypertension, dyslipidemia, and hyperthyroidism who developed severe retrosternal pain, reflux, persistent vomiting, and oral intolerance 5 days after balloon placement. Computed tomography showed appropriate balloon position without migration or perforation but suggested a small hiatal hernia. Due to refractory symptoms, laparoscopic balloon removal was performed. Intraoperative findings revealed a larger hiatal hernia with paraesophageal lipoma than previously identified, prompting simultaneous hiatoplasty and conversion to Roux-en-Y gastric bypass. The patient had progressive postoperative recovery with symptom resolution and improved oral tolerance. This case highlights that severe balloon intolerance may reveal occult hiatal pathology despite inconclusive preoperative studies and demonstrates that single-stage laparoscopic balloon removal, hiatal hernia repair, and definitive bariatric surgery can be a safe, effective strategy in appropriately selected patients.

4 July 2026 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
MGMaximo V Torres Guaicha
Maximo V Torres Guaicha
ACAlberto C Gordillo Calero
Alberto C Gordillo Calero
TOTabata L Tinoco Ortiz
Tabata L Tinoco Ortiz
Paul Mateo Tovar CobosPaul Mateo Tovar Cobos
Paul Mateo Tovar Cobos
Endoscopic gastric plication (EGP), also known as endoscopic sleeve gastroplasty, is a minimally invasive bariatric procedure that reduces gastric volume through full thickness endoluminal suturing. It has demonstrated aiding weight loss and improvement in obesity-related comorbidities. It is considered safe, with low rates of severe adverse events, but early and long-term complications remain insufficiently characterized. We report two cases of EGP-related complications. The first case involves a 31-year-old woman who presented 2 years after the procedure with persistent dyspepsia and recurrent gain due to suture dehiscence, requiring conversion to Roux-en-Y gastric bypass with removal of gastric remanent. The second case describes a 24-year-old woman who developed an early postoperative hemorrhagic complication secondary to gastroepiploic vessel injury, requiring urgent surgical intervention. These cases illustrate potential EGP severe complications, ranging from early acute life-threatening events to late structural failure, emphasizing the importance of high suspicion, timely diagnosis and individualized management strategies.